Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Recruiting
Phase 2
Interventional Study
Asplenia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 75 (estimated)
- Sponsor
- University of California, Davis · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, em…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury.
Exclusion Criteria:
* Ages less than 18 and greater than 65
* Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.
Contacts